Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Irene Y Cheung

Showing results (21-30 of 49) with videos related to

Pageof 5
Sort By:
Cancer|July 13, 2002
Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8Irene Y Cheung, M Serena Lo Piccolo, Nancy Collins, et al.
Oncoimmunology|June 27, 2013
Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-<i>D</i>-glucan: A Phase I study in patients with chemoresistant neuroblastomaShakeel Modak, Brian H Kushner, Kim Kramer, et al.
International Journal of Cancer|December 15, 2010
Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastomaHong Xu, Irene Y Cheung, Xiao X Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastomaIrene Y Cheung, M Serena Lo Piccolo, Brian H Kushner, et al.
Genes, Chromosomes & Cancer|October 15, 2013
Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastasesDavid Cobrinik, Irina Ostrovnaya, Maryam Hassimi, et al.
JAMA Oncology|October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical TrialBrian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Novel markers of subclinical disease for Ewing family tumors from gene expression profilingIrene Y Cheung, Yi Feng, Karen Danis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factorNai-Kong V Cheung, Rebecca Sowers, Andrew J Vickers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.
Vaccines|June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer VaccineIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Pageof 5

Showing results (21-30 of 49) with videos related to

Sort By:
Pageof 5
Cancer|July 13, 2002
Quantitation of GD2 synthase mRNA by real-time reverse transcription-polymerase chain reaction: utility in bone marrow purging of neuroblastoma by anti-GD2 antibody 3F8Irene Y Cheung, M Serena Lo Piccolo, Nancy Collins, et al.
Oncoimmunology|June 27, 2013
Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-<i>D</i>-glucan: A Phase I study in patients with chemoresistant neuroblastomaShakeel Modak, Brian H Kushner, Kim Kramer, et al.
International Journal of Cancer|December 15, 2010
Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastomaHong Xu, Irene Y Cheung, Xiao X Wei, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 15, 2003
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastomaIrene Y Cheung, M Serena Lo Piccolo, Brian H Kushner, et al.
Genes, Chromosomes & Cancer|October 15, 2013
Recurrent pre-existing and acquired DNA copy number alterations, including focal TERT gains, in neuroblastoma central nervous system metastasesDavid Cobrinik, Irina Ostrovnaya, Maryam Hassimi, et al.
JAMA Oncology|October 17, 2018
Humanized 3F8 Anti-GD2 Monoclonal Antibody Dosing With Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Resistant Neuroblastoma: A Phase 1 Clinical TrialBrian H Kushner, Irene Y Cheung, Shakeel Modak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2007
Novel markers of subclinical disease for Ewing family tumors from gene expression profilingIrene Y Cheung, Yi Feng, Karen Danis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 10, 2006
FCGR2A polymorphism is correlated with clinical outcome after immunotherapy of neuroblastoma with anti-GD2 antibody and granulocyte macrophage colony-stimulating factorNai-Kong V Cheung, Rebecca Sowers, Andrew J Vickers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 8, 2012
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remissionNai-Kong V Cheung, Irene Y Cheung, Brian H Kushner, et al.
Vaccines|June 27, 2024
Long Prime-Boost Interval and Heightened Anti-GD2 Antibody Response to Carbohydrate Cancer VaccineIrene Y Cheung, Audrey Mauguen, Shakeel Modak, et al.
Pageof 5